Pharmaceutical company “AstraZeneca” signed an agreement on the supply of 1.3 billion doses of vaccines against coronavirus infection in India and other developing countries, according to a press release received in the editorial office Remedium.ru. Deliveries should start before the end of 2020. The company has previously committed to issue at the same time, 400 million vaccine doses for the UK and the USA.
The vaccine, referred to in the agreements is developed by the University of Oxford, now the developers have begun to set dobrovltsev to participate in the II/III phase KI of the drug.
According to the agreement with Coalition for innovation in the field of epidemic preparedness (CEPI) and the Global Alliance for vaccines and immunization (GAVI), the company will supply 300 million doses of vaccine and will begin shipping by the end of the year. Agreement with serum Institute of India provides for the supply of 1 billion doses of vaccines for countries with low and middle income 400 million of which must be delivered before the end of this year.
Production capacity prepared by AstraZeneca for the release of the vaccine can produce up to 2 billion doses of the drug, the report says.
The vaccine, developed by the Jenner Institute at Oxford University and license agreement with AstraZeneca called AZD1222 created on the basis of devoid of the capacity for replication of adenovirus is causing the infection in chimpanzees (vector). The structure of the virus is embedded a fragment of the genome of the pathogen COVID-19, encodes the protein its thorn. To date, vaccines tested more than 320 volunteers, the test results demonstrate the safety and good tolerability.